Education
About Us
Working with TipRanks
Follow Us
Adaptimmune Therapeutics (ADAP)
NASDAQ:ADAP
RESEARCH TOOLSreports
Total Valuation
Adaptimmune Therapeutics has a market cap or net worth of $59.86M. The enterprise value is $60.48M.
Market Cap$59.86M
Enterprise Value$60.48M
Share Statistics
Adaptimmune Therapeutics has 257.23M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding257.23M
Owned by Insiders48.53%
Owned by Instutions0.01%
Financial Efficiency
Adaptimmune Therapeutics’s return on equity (ROE) is -5.98 and return on invested capital (ROIC) is -38.90%.
Return on Equity (ROE)-597.64%
Return on Assets (ROA)-28.79%
Return on Invested Capital (ROIC)-38.90%
Return on Capital Employed (ROCE)-37.90%
Revenue Per Employee$351,841.897
Profits Per Employee-$139,948.617
Employee Count506
Asset Turnover0.72
Inventory Turnover<0.01
Valuation Ratios
The current PE Ratio of Adaptimmune Therapeutics is -1.92. Adaptimmune Therapeutics’s PEG ratio is 0.04.
PE Ratio-1.92
PS Ratio0.76
PB Ratio11.47
Price to Fair Value11.47
Price to FCF-1.86
Price to Operating Cash Flow-1.86
PEG Ratio0.04
Income Statement
In the last 12 months, Adaptimmune Therapeutics had revenue of $178.03M and earned -$70.81M in profits. Earnings per share was -$0.05.
Revenue$178.03M
Gross Profit$172.60M
Operating Income-$68.76M
Pretax Income-$69.54M
Net Income-$70.81M
EBITDA-56.25M
Earnings Per Share (EPS)-0.05
Cash Flow
In the last 12 months, operating cash flow was -$73.20M and capital expenditures -$2.72M, giving a free cash flow of -$75.92M billion.
Operating Cash Flow-$73.20M
Free Cash Flow-$75.92M
Free Cash Flow per Share-$0.30
Dividends & Yields
Adaptimmune Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-8.98%
Earnings Yield-52.10%
Stock Price Statistics
Beta0.62
52-Week Price Change-75.73%
50-Day Moving Average0.42
200-Day Moving Average0.77
Relative Strength Index (RSI)39.08
Average Volume (3m)2.55M
Important Dates
Adaptimmune Therapeutics upcoming earnings date is May 15, 2025, Before Open.
Last Earnings DateMar 20, 2025
Next Earnings DateMay 15, 2025
Ex-Dividend Date―
Financial Position
Adaptimmune Therapeutics as a current ratio of 2.92, with Debt / Equity ratio of 2.02
Current Ratio2.92
Quick Ratio2.80
Debt to Market Cap0.18
Net Debt to EBITDA1.28
Interest Coverage Ratio-20.54
Taxes
In the past 12 months, Adaptimmune Therapeutics has paid $141.92K in taxes.
Income Tax$141.92K
Effective Tax Rate-5.32%
Enterprise Valuation
Adaptimmune Therapeutics EV to EBITDA ratio is -14.21, with an EV/FCF ratio of -10.22.
EV to Sales4.20
EV to EBITDA-14.21
EV to Free Cash Flow-10.22
EV to Operating Cash Flow-10.22
Balance Sheet
Adaptimmune Therapeutics has $151.60M in cash and marketable securities with $74.21M in debt, giving a net cash position of -$77.40M billion.
Cash & Marketable Securities$151.60M
Total Debt$74.21M
Net Cash-$77.40M
Net Cash Per Share-$0.30
Tangible Book Value Per Share<$0.01
Margins
Gross margin is 99.96%, with operating margin of -38.62%, and net profit margin of -39.78%.
Gross Margin99.96%
Operating Margin-38.62%
Pretax Margin-37.77%
Net Profit Margin-39.78%
EBITDA Margin-29.58%
EBIT Margin-35.89%
Analyst Forecast
The average price target for Adaptimmune Therapeutics is $1.78, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$1.78
Price Target Upside612.00%
Analyst ConsensusModerate Buy
Analyst Count7
Revenue Growth Forecast194.23%
EPS Growth Forecast45.50%